Citations (106)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Yao Wang, Amy Patel & Raymond S Douglas. (2019) Thyroid Eye Disease: How A Novel Therapy May Change The Treatment Paradigm. Therapeutics and Clinical Risk Management 15, pages 1305-1318.
Read now
Read now
Terry J. Smith. (2017) TSHR as a therapeutic target in Graves’ disease. Expert Opinion on Therapeutic Targets 21:4, pages 427-432.
Read now
Read now
Mohd Shazli Draman & Marian Ludgate. (2016) Thyroid eye disease- an update. Expert Review of Ophthalmology 11:4, pages 273-284.
Read now
Read now
Terry J. Smith. (2016) Rationale for therapeutic targeting insulin-like growth factor-1 receptor and bone marrow-derived fibrocytes in thyroid-associated ophthalmopathy. Expert Review of Ophthalmology 11:2, pages 77-79.
Read now
Read now
Annamaria Erdei, Gyorgy Paragh, Peter Kovacs, Zsolt Karanyi, Ervin Berenyi, Laszlo Galuska, Agota Lenkey, Lajos Szabados, Ferenc Gyory, Bernadett Ujhelyi, Andras Berta, Judit Boda, Eszter Berta, Miklos Bodor, Annamaria Gazdag & Endre V. Nagy. (2014) Rapid response to and long-term effectiveness of anti-CD20 antibody in conventional therapy resistant Graves’ orbitopathy: A five-year follow-up study. Autoimmunity 47:8, pages 548-555.
Read now
Read now
Vahab Fatourechi. (2011) Thyroid dermopathy and acropachy. Expert Review of Dermatology 6:1, pages 75-90.
Read now
Read now
Knut Eichhorn, Andrew R Harrison, Erick D Bothun, Linda K McLoon & Michael S Lee. (2010) Ocular treatment of thyroid eye disease. Expert Review of Ophthalmology 5:3, pages 313-325.
Read now
Read now
Terry J. Smith. (2003) The Putative Role of Fibroblasts in the Pathogenesis of Graves' Disease: Evidence for the Involvement of the Insulin-like Growth Factor-1 Receptor in Fibroblast Activation. Autoimmunity 36:6-7, pages 409-415.
Read now
Read now
Articles from other publishers (98)
Terry J. Smith. (2023) Fibrocyte Participation in Thyroid-Associated Ophthalmopathy Suggests New Approaches to Therapy. Ophthalmic Plastic & Reconstructive Surgery 39:6S, pages S9-S18.
Crossref
Crossref
Ling Wang, Meng Zhang, Yue Wang & Bingyin Shi. (2023) Graves’ Orbitopathy Models: Valuable Tools for Exploring
Pathogenesis and Treatment. Hormone and Metabolic Research 55:11, pages 745-751.
Crossref
Crossref
Xuejiao Cui, Futao Wang & Cong Liu. (2023) A review of TSHR- and IGF-1R-related pathogenesis and treatment of Graves’ orbitopathy. Frontiers in Immunology 14.
Crossref
Crossref
Pengbo Zhang & Huang Zhu. (2022) Cytokines in Thyroid-Associated Ophthalmopathy. Journal of Immunology Research 2022, pages 1-12.
Crossref
Crossref
Luigi Bartalena & Maria Laura Tanda. (2022) Current concepts regarding Graves’ orbitopathy. Journal of Internal Medicine 292:5, pages 692-716.
Crossref
Crossref
Terry J Smith. (2022) Understanding Pathogenesis Intersects With Effective Treatment for Thyroid Eye Disease. The Journal of Clinical Endocrinology & Metabolism 107:Supplement_1, pages S13-S26.
Crossref
Crossref
Leonard Girnita, Terry J Smith & Joseph A M J L Janssen. (2022) It Takes Two to Tango: IGF-I and TSH Receptors in Thyroid Eye Disease. The Journal of Clinical Endocrinology & Metabolism 107:Supplement_1, pages S1-S12.
Crossref
Crossref
Xing Wang, Shenglan YangHuijing YeJingqiao ChenLu ShiLujia FengXiandai WangTe ZhangRongxin ChenWei XiaoHuasheng Yang. (2022)
Disulfiram Exerts Antiadipogenic, Anti-Inflammatory, and Antifibrotic Therapeutic Effects in an
In Vitro
Model of Graves' Orbitopathy
. Thyroid 32:3, pages 294-305.
Crossref
Crossref
E. J. Neag & T. J. Smith. (2021) 2021 update on thyroid-associated ophthalmopathy. Journal of Endocrinological Investigation 45:2, pages 235-259.
Crossref
Crossref
CarolineY Yu, RebeccaL Ford, SaraT Wester & ErinM Shriver. (2022) Update on thyroid eye disease: Regional variations in prevalence, diagnosis, and management. Indian Journal of Ophthalmology 70:7, pages 2335.
Crossref
Crossref
Huihui Zou, Weiwei Xu, Ying Wang & Zhihong Wang. (2021) A data-driven approach for the discovery of biomarkers associated with thyroid eye disease. BMC Ophthalmology 21:1.
Crossref
Crossref
Mohd Shazli Draman, Lei Zhang, Colin Dayan & Marian Ludgate. (2021) Orbital Signaling in Graves’ Orbitopathy. Frontiers in Endocrinology 12.
Crossref
Crossref
Bryan J. Winn & Robert C. Kersten. (2021) Teprotumumab. Ophthalmology 128:11, pages 1627-1651.
Crossref
Crossref
Lu Shi, Huijing Ye, Jun Huang, Yanbing Li, Xing Wang, Zhihui Xu, Jingqiao Chen, Wei Xiao, Rongxin Chen & Huasheng Yang. (2021) IL-38 Exerts Anti-Inflammatory and Antifibrotic Effects in Thyroid-Associated Ophthalmopathy. The Journal of Clinical Endocrinology & Metabolism 106:8, pages e3125-e3142.
Crossref
Crossref
Nicholas R. Mahoney & Fatemeh Rajaii. (2021) Current Management of Thyroid Eye Disease. Current Treatment Options in Neurology 23:7.
Crossref
Crossref
Terry J. Smith. (2021) Insulin-Like Growth Factor Pathway and the Thyroid. Frontiers in Endocrinology 12.
Crossref
Crossref
Tomasz Bednarczuk & Simon H Pearce. (2021) The knowns and unknowns of teprotumumab for thyroid eye disease. The Lancet Diabetes & Endocrinology 9:6, pages 323-325.
Crossref
Crossref
Yizhi Ding, Shaoqin Yang & Hua Gao. (2021) Teprotumumab: The Dawn of Therapies in Moderate-to-Severe Thyroid-Associated Ophthalmopathy. Hormone and Metabolic Research 53:04, pages 211-218.
Crossref
Crossref
Amy P. Jain, Pimkwan Jaru‐Ampornpan & Raymond S. Douglas. (2021) Thyroid eye disease: Redefining its management—A review. Clinical & Experimental Ophthalmology 49:2, pages 203-211.
Crossref
Crossref
Joseph A.M.J.L. Janssen & Terry J. Smith. (2021) Lessons Learned from Targeting IGF-I Receptor in Thyroid-Associated Ophthalmopathy. Cells 10:2, pages 383.
Crossref
Crossref
Jingran Cao & Douglas Yee. (2021) Disrupting Insulin and IGF Receptor Function in Cancer. International Journal of Molecular Sciences 22:2, pages 555.
Crossref
Crossref
Thai H. Do & Alon Kahana. (2021) Thyroid Eye Disease: Pathogenic Risk Factors. International Ophthalmology Clinics 61:2, pages 3-20.
Crossref
Crossref
Nupur Kikani & Ruchi Gaba. (2021) Primer on Graves’ Disease: What the Ophthalmologist Should Know and Do. International Ophthalmology Clinics 61:2, pages 21-31.
Crossref
Crossref
Anaïs L. Carniciu & Alon Kahana. 2021. Smith and Nesi’s Ophthalmic Plastic and Reconstructive Surgery. Smith and Nesi’s Ophthalmic Plastic and Reconstructive Surgery
983
999
.
Katarzyna Gontarz-Nowak, Magdalena Szychlińska, Wojciech Matuszewski, Magdalena Stefanowicz-Rutkowska & Elżbieta Bandurska-Stankiewicz. (2020) Current Knowledge on Graves’ Orbitopathy. Journal of Clinical Medicine 10:1, pages 16.
Crossref
Crossref
Terry J. Smith. (2020) Teprotumumab as a Novel Therapy for Thyroid-Associated Ophthalmopathy. Frontiers in Endocrinology 11.
Crossref
Crossref
George J Kahaly. (2020) Management of Graves Thyroidal and Extrathyroidal Disease: An Update. The Journal of Clinical Endocrinology & Metabolism 105:12, pages 3704-3720.
Crossref
Crossref
R. Gärtner & S. Nitschmann. (2020) Teprotumumab bei schilddrüsenassoziierter OphthalmopathieTeprotumumab for thyroid-associated ophthalmopathy. Der Internist 61:11, pages 1208-1210.
Crossref
Crossref
Christine C. Krieger, Susanne Neumann & Marvin C. Gershengorn. (2020) Is There Evidence for IGF1R-Stimulating Abs in Graves’ Orbitopathy Pathogenesis?. International Journal of Molecular Sciences 21:18, pages 6561.
Crossref
Crossref
Terry F. Davies, Stig Andersen, Rauf Latif, Yuji Nagayama, Giuseppe Barbesino, Maria Brito, Anja K. Eckstein, Alex Stagnaro-Green & George J. Kahaly. (2020) Graves’ disease. Nature Reviews Disease Primers 6:1.
Crossref
Crossref
G. Lanzolla, D. Ricci, F. Nicolì, E. Sabini, A. Sframeli, A. Brancatella, M. Mantuano, G. R. Dottore, I. Bucci, M. Figus, M. Nardi, F. Latrofa, C. Marcocci & M. Marinò. (2020) Putative protective role of autoantibodies against the insulin-like growth factor-1 receptor in Graves’ Disease: results of a pilot study. Journal of Endocrinological Investigation.
Crossref
Crossref
Terry J. Smith. (2020) Teprotumumab in Thyroid-Associated Ophthalmopathy: Rationale for Therapeutic Insulin-Like Growth Factor–I Receptor Inhibition. Journal of Neuro-Ophthalmology 40:1, pages 74-83.
Crossref
Crossref
Marius N. StanJ. Paul Banga. (2020) Teprotumumab Significantly Improves Active Moderate-to-Severe Thyroid Eye Disease. Clinical Thyroidology 32:3, pages 114-116.
Crossref
Crossref
Peter N. Taylor, Lei Zhang, Richard W. J. Lee, Ilaria Muller, Daniel G. Ezra, Colin M. Dayan, George J. Kahaly & Marian Ludgate. (2019) New insights into the pathogenesis and nonsurgical management of Graves orbitopathy. Nature Reviews Endocrinology 16:2, pages 104-116.
Crossref
Crossref
Tauseef Nabi & Nadeema Rafiq. (2020) Factors associated with severity of orbitopathy in patients with Graves' disease. Taiwan Journal of Ophthalmology 10:3, pages 197.
Crossref
Crossref
Alan Chun Hong Lee & George J. Kahaly. (2020) Novel Approaches for Immunosuppression in Graves’ Hyperthyroidism and Associated Orbitopathy. European Thyroid Journal 9:Suppl. 1, pages 17-30.
Crossref
Crossref
Terry J. Smith. (2020) Teprotumumab Treatment for Thyroid-Associated Ophthalmopathy. European Thyroid Journal 9:Suppl. 1, pages 31-39.
Crossref
Crossref
Terry J. Smith. (2020) Thyroid-associated ophthalmopathy: Emergence of teprotumumab as a promising medical therapy. Best Practice & Research Clinical Endocrinology & Metabolism 34:1, pages 101383.
Crossref
Crossref
Amy Patel, Huasheng Yang & Raymond S. Douglas. (2019) A New Era in the Treatment of Thyroid Eye Disease. American Journal of Ophthalmology 208, pages 281-288.
Crossref
Crossref
Eliot Osher & Valentine M. Macaulay. (2019) Therapeutic Targeting of the IGF Axis. Cells 8:8, pages 895.
Crossref
Crossref
M. Marinò, G. Rotondo Dottore, I. Ionni, G. Lanzolla, E. Sabini, D. Ricci, A. Sframeli, B. Mazzi, F. Menconi, F. Latrofa, P. Vitti, C. Marcocci & L. Chiovato. (2018) Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves’ disease and Graves’ orbitopathy. Journal of Endocrinological Investigation 42:4, pages 471-480.
Crossref
Crossref
Terry J Smith & Joseph A M J L Janssen. (2019) Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy. Endocrine Reviews 40:1, pages 236-267.
Crossref
Crossref
Terry J. Smith. (2018) The insulin-like growth factor-I receptor and its role in thyroid-associated ophthalmopathy. Eye 33:2, pages 200-205.
Crossref
Crossref
Terry J. Smith. (2019) Challenges in Orphan Drug Development: Identification of Effective Therapy for Thyroid-Associated Ophthalmopathy. Annual Review of Pharmacology and Toxicology 59:1, pages 129-148.
Crossref
Crossref
Petros Perros. (2018) A decade of thyroidology. Hormones 17:4, pages 491-495.
Crossref
Crossref
Stephen W. Spaulding. (2018) Do High Levels of Antibodies to the IGF-1 Receptor Ameliorate Orbitopathy in Some Patients with Graves’ Disease?. Clinical Thyroidology 30:10, pages 464-467.
Crossref
Crossref
Michelle Mohyi & Terry J Smith. (2018) 40 YEARS OF IGF1: IGF1 receptor and thyroid-associated ophthalmopathy. Journal of Molecular Endocrinology 61:1, pages T29-T43.
Crossref
Crossref
Bernice Marcus-SamuelsChristine C. KriegerAlisa BoutinGeorge J. KahalySusanne NeumannMarvin C. Gershengorn. (2018) Evidence That Graves' Ophthalmopathy Immunoglobulins Do Not Directly Activate IGF-1 Receptors. Thyroid 28:5, pages 650-655.
Crossref
Crossref
Terry J Smith. (2018) New advances in understanding thyroid-associated ophthalmopathy and the potential role for insulin-like growth factor-I receptor. F1000Research 7, pages 134.
Crossref
Crossref
Claudio Marcocci & Terry J. Smith. 2018. Thyroid Diseases. Thyroid Diseases
451
488
.
Terry J. Smith, George J. Kahaly, Daniel G. Ezra, James C. Fleming, Roger A. Dailey, Rosa A. Tang, Gerald J. Harris, Alessandro Antonelli, Mario Salvi, Robert A. Goldberg, James W. Gigantelli, Steven M. Couch, Erin M. Shriver, Brent R. Hayek, Eric M. Hink, Richard M. Woodward, Kathleen Gabriel, Guido Magni & Raymond S. Douglas. (2017) Teprotumumab for Thyroid-Associated Ophthalmopathy. New England Journal of Medicine 376:18, pages 1748-1761.
Crossref
Crossref
Terry J. Smith & Joseph A. M. J. L. Janssen. (2017) Building the Case for Insulin-Like Growth Factor Receptor-I Involvement in Thyroid-Associated Ophthalmopathy. Frontiers in Endocrinology 7.
Crossref
Crossref
Christine C. Krieger, Robert F. Place, Carmine Bevilacqua, Bernice Marcus-Samuels, Brent S. Abel, Monica C. Skarulis, George J. Kahaly, Susanne Neumann & Marvin C. Gershengorn. (2016) TSH/IGF-1 Receptor Cross Talk in Graves' Ophthalmopathy Pathogenesis. The Journal of Clinical Endocrinology & Metabolism 101:6, pages 2340-2347.
Crossref
Crossref
Terry F. Davies, Peter Laurberg & Rebecca S. Bahn. 2016. Williams Textbook of Endocrinology. Williams Textbook of Endocrinology
369
415
.
Claudio Marcocci & Terry J. Smith. 2017. Thyroid Diseases. Thyroid Diseases
1
39
.
J. Paul Banga, Sajad Moshkelgosha, Utta Berchner-Pfannschmidt & Anja Eckstein. 2016. Animal Models of Ophthalmic Diseases. Animal Models of Ophthalmic Diseases
117
126
.
J. P. Banga, S. Moshkelgosha, U. Berchner-Pfannschmidt & A. Eckstein. (2015) Modeling Graves’ Orbitopathy in Experimental Graves’
Disease. Hormone and Metabolic Research 47:10, pages 797-803.
Crossref
Crossref
R. S. Bahn. (2015) Current Insights into the Pathogenesis of Graves’
Ophthalmopathy. Hormone and Metabolic Research 47:10, pages 773-778.
Crossref
Crossref
Terry J. Smith. (2015) TSH-receptor-expressing fibrocytes and thyroid-associated ophthalmopathy. Nature Reviews Endocrinology 11:3, pages 171-181.
Crossref
Crossref
Rebecca S. Bahn. 2015. Graves' Disease. Graves' Disease
179
185
.
Terry J. Smith. 2015. Thyroid Eye Disease. Thyroid Eye Disease
23
32
.
Bokkwan Jun & Prem S. Subramanian. 2015. Thyroid Eye Disease. Thyroid Eye Disease
99
114
.
L. Zhang, F. Grennan-Jones, M. S. Draman, C. Lane, D. Morris, C. M. Dayan, A. R. Tee & M. Ludgate. (2014) Possible Targets for Nonimmunosuppressive Therapy of Graves' Orbitopathy. The Journal of Clinical Endocrinology & Metabolism 99:7, pages E1183-E1190.
Crossref
Crossref
Allison N. McCoy, Denise S. Kim, Erin F. Gillespie, Stephen J. Atkins, Terry J. Smith & Raymond S. Douglas. (2014) Rituximab (Rituxan) Therapy for Severe Thyroid-Associated Ophthalmopathy Diminishes IGF-1R+ T Cells. The Journal of Clinical Endocrinology & Metabolism 99:7, pages E1294-E1299.
Crossref
Crossref
Shannon J. C. Shan & Raymond S. Douglas. (2014) The Pathophysiology of Thyroid Eye Disease. Journal of Neuro-Ophthalmology 34:2, pages 177-185.
Crossref
Crossref
Sajad Moshkelgosha, Po-Wah So, Neil Deasy, Salvador Diaz-Cano & J Paul Banga. (2013) Cutting Edge: Retrobulbar Inflammation, Adipogenesis, and Acute Orbital Congestion in a Preclinical Female Mouse Model of Graves' Orbitopathy Induced by Thyrotropin Receptor Plasmid-in Vivo Electroporation. Endocrinology 154:9, pages 3008-3015.
Crossref
Crossref
Aimee J. Varewijck, Anita Boelen, Steven W. J. Lamberts, Eric Fliers, Leo J. Hofland, Wilmar M. Wiersinga & Joseph A. M. J. L. Janssen. (2013) Circulating IgGs May Modulate IGF-I Receptor Stimulating Activity in a Subset of Patients With Graves' Ophthalmopathy. The Journal of Clinical Endocrinology & Metabolism 98:2, pages 769-776.
Crossref
Crossref
Pingqian Zhao, Yuan Deng, Ping Gu, Yefei Wang, Huifang Zhou, Yamin Hu, Ping Chen & Xianqun Fan. (2013) Insulin-like growth factor 1 promotes the proliferation and adipogenesis of orbital adipose-derived stromal cells in thyroid-associated ophthalmopathy. Experimental Eye Research 107, pages 65-73.
Crossref
Crossref
Terry J. Smith, Laszlo Hegedüs & Raymond S. Douglas. (2012) Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves’ orbitopathy. Best Practice & Research Clinical Endocrinology & Metabolism 26:3, pages 291-302.
Crossref
Crossref
Daniel J. Gould, Forrest S. Roth & Charles N. S. Soparkar. (2011) The Diagnosis and Treatment of Thyroid-Associated Ophthalmopathy. Aesthetic Plastic Surgery 36:3, pages 638-648.
Crossref
Crossref
Delu Song, Renyan Wang, Yong Zhong, Weiye Li, Hui Li & Fangtian Dong. (2011) Locally produced insulin-like growth factor-1 by orbital fibroblasts as implicative pathogenic factor rather than systemically circulated IGF-1 for patients with thyroid-associated ophthalmopathy. Graefe's Archive for Clinical and Experimental Ophthalmology 250:3, pages 433-440.
Crossref
Crossref
Lei Zhang, Fiona Grennan-Jones, Carol Lane, D. Aled Rees, Colin M. Dayan & Marian Ludgate. (2012) Adipose Tissue Depot-Specific Differences in the Regulation of Hyaluronan Production of Relevance to Graves' Orbitopathy. The Journal of Clinical Endocrinology & Metabolism 97:2, pages 653-662.
Crossref
Crossref
Shuang-Xia Zhao, Shanli Tsui, Anthony Cheung, Raymond S Douglas, Terry J Smith & J Paul Banga. (2011) Orbital fibrosis in a mouse model of Graves' disease induced by genetic immunization of thyrotropin receptor cDNA. Journal of Endocrinology 210:3, pages 369-377.
Crossref
Crossref
Tereza PlanckHemang ParikhHåkan BrorsonTuve MårtenssonPeter ÅsmanLeif GroopBengt HallengrenMikael Lantz. (2011) Gene Expression in Graves' Ophthalmopathy and Arm Lymphedema: Similarities and Differences. Thyroid 21:6, pages 663-674.
Crossref
Crossref
Susan J. Mandel, P. Reed Larsen & Terry F. Davies. 2011. Williams Textbook of Endocrinology. Williams Textbook of Endocrinology
362
405
.
Terry J. Smith. (2010) Insulin-Like Growth Factor-I Regulation of Immune Function: A Potential Therapeutic Target in Autoimmune Diseases?. Pharmacological Reviews 62:2, pages 199-236.
Crossref
Crossref
T. J. Smith. (2014) Pathogenesis of Graves’ orbitopathy: A 2010 update. Journal of Endocrinological Investigation 33:6, pages 414-421.
Crossref
Crossref
Petros Perros & Gerasimos E. Krassas. (2009) Graves orbitopathy: a perspective. Nature Reviews Endocrinology 5:6, pages 312-318.
Crossref
Crossref
Raymond S. Douglas, Thomas H. Brix, Catherine J. Hwang, Laszlo Hegedüs & Terry J. Smith. (2009) Divergent Frequencies of IGF-I Receptor-Expressing Blood Lymphocytes in Monozygotic Twin Pairs Discordant for Graves’ Disease: Evidence for a Phenotypic Signature Ascribable to Nongenetic Factors. The Journal of Clinical Endocrinology & Metabolism 94:5, pages 1797-1802.
Crossref
Crossref
Luigi Bartalena & Maria Laura Tanda. (2009) Graves' Ophthalmopathy. New England Journal of Medicine 360:10, pages 994-1001.
Crossref
Crossref
Brian Shine. 2008. Garner and Klintworth's Pathobiology of Ocular Disease, Third Edition. Garner and Klintworth's Pathobiology of Ocular Disease, Third Edition
1037
1047
.
Wilmar M. Wiersinga. 2008. Autoimmune Diseases in Endocrinology. Autoimmune Diseases in Endocrinology
193
214
.
Teck Kim KhooRebecca S. Bahn. (2007) Pathogenesis of Graves' Ophthalmopathy: The Role of Autoantibodies. Thyroid 17:10, pages 1013-1018.
Crossref
Crossref
G.E. Krassas & A. Gogakos. (2006) Thyroid-associated Ophthalmopathy in Juvenile Graves' Disease- Clinical, Endocrine and Therapeutic Aspects. Journal of Pediatric Endocrinology and Metabolism 19:10.
Crossref
Crossref
H. A. Drexhage. (2006) Are There More than Antibodies to the Thyroid-Stimulating Hormone Receptor that Meet the Eye in Graves’ Disease?. Endocrinology 147:1, pages 9-12.
Crossref
Crossref
T J Smith. (2005) Insights into the role of fibroblasts in human autoimmune diseases. Clinical and Experimental Immunology 141:3, pages 388-397.
Crossref
Crossref
S. Kloprogge, L. Kowal, J. Wall & A.G. Frauman. (2018) The Clinicopathologic Basis of Graves' Ophthalmopathy: A Review. European Journal of Ophthalmology 15:3, pages 315-323.
Crossref
Crossref
Luigi Bartalena, W. M. Wiersinga & A. Pinchera. (2014) Graves? ophthalmopathy: State of the art and perspectives. Journal of Endocrinological Investigation 27:3, pages 295-301.
Crossref
Crossref
Terry J. Smith. (2014) Novel aspects of orbital fibroblast pathology. Journal of Endocrinological Investigation 27:3, pages 246-253.
Crossref
Crossref
Bellur S. Prabhakar, Rebecca S. Bahn & Terry J. Smith. (2003) Current Perspective on the Pathogenesis of Graves’ Disease and Ophthalmopathy. Endocrine Reviews 24:6, pages 802-835.
Crossref
Crossref
Jane Pritchard, Rui Han, Noah Horst, William W. Cruikshank & Terry J. Smith. (2003) Immunoglobulin Activation of T Cell Chemoattractant Expression in Fibroblasts from Patients with Graves’ Disease Is Mediated Through the Insulin-Like Growth Factor I Receptor Pathway. The Journal of Immunology 170:12, pages 6348-6354.
Crossref
Crossref
Terry J. Smith. (2002) Fibroblast biology in thyroid diseases. Current Opinion in Endocrinology & Diabetes 9:5, pages 393-400.
Crossref
Crossref
Jane Pritchard, Noah Horst, William Cruikshank & Terry J. Smith. (2002) Igs from Patients with Graves’ Disease Induce the Expression of T Cell Chemoattractants in Their Fibroblasts. The Journal of Immunology 168:2, pages 942-950.
Crossref
Crossref
Anthony P. Weetman, E. Helen Kemp, Jonathan N. Ridgway & Philip F. Watson. 2001. Thyroid Eye Disease. Thyroid Eye Disease
1
20
.
Anthony P. Weetman. 1999. Autoimmune Endocrinopathies. Autoimmune Endocrinopathies
245
270
.
V. Nebes & J. Wall. 2011. Comprehensive Physiology. Comprehensive Physiology
293
324
.
F.G.A. DELEMARRE, P.J. SIMONS & H.A. DREXHAGE. (1996) Histomorphological Aspects of the Development of Thyroid Autoimmune Diseases: Consequences for Our Understanding of Endocrine Ophthalmopathy. Thyroid 6:4, pages 369-377.
Crossref
Crossref
Petros Perros & Pat Kendall-Taylor. (1995) Thyroid-associated ophthalmopathy: pathogenesis and clinical management. Baillière's Clinical Endocrinology and Metabolism 9:1, pages 115-135.
Crossref
Crossref